ArticleFrontiers in immunology2026
Astilbin: a novel therapeutic strategy for bone destruction in rheumatoid arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone destruction constitutes the primary cause of disability in rheumatoid arthritis (RA). Herbal medicines feature unique multi-target advantages, rendering them promising therapeutic candidates for attenuating RA-associated bone damage. Objective: This study aimed to investigate the therapeutic efficacy and underlying mechanisms of astilbin, a core bioactive flavonoid extracted from Tufuling (Smilax glabra), against bone destruction in RA. Methods: A CIA mouse model was established via tail vein injection of type II collagen. Micro-CT, HE staining and TRAP staining were applied to evaluate the inhibitory and therapeutic effects of astilbin on RA bone destruction. Network pharmacology and bioinformatics analyses were performed to screen the potential targets and signaling pathways of astilbin for RA treatment. Mendelian randomization analysis was further conducted to genetically validate the correlation between candidate genes and RA. Molecular docking was utilized to calculate binding energies between astilbin and core pathogenic targets of RA. Immunofluorescence, elisa, WB and qPCR were adopted to verify the key targets and anti-inflammatory activity of astilbin in ameliorating RA bone erosion. Results: Conclusion: Astilbin may exert multiple pharmacological effects including anti-inflammation, inhibition of osteoclast activation, improvement of bone microarchitecture and alleviation of bone destruction in RA via regulating the MAPK signaling pathway, and it exhibits favorable safety
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.